Supporting people who use drugs & providers: hep C info & care Magdalena Harris London School of Hygiene and Tropical Medicine

Slides:



Advertisements
Similar presentations
Txt2stop - mobile phones based smoking cessation support A systematic review of mobile phone based trials for NCD Dr Cari Free Clinical Senior lecturer.
Advertisements

Medical Technology By Melissa G. Jackie G. Lizette P. Stephanie M.
Effective treatment. Changing lives Needs Assessment Tools Past, Present and Future Data and methods available for carrying out needs assessment 25 th.
10 year history serving the Substance Use needs of Londons LGBT ( L esbian, G ay, B isexual & T ransgender) community 8,000 contacts, 700+ people in various.
Injecting and BBVs – NDTMS and prevalence data Current prevalence data for injecting among opiate/crack users (2010/11) shows continuation of a steady.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the UK – 30 years on… Since 1981: 122,000 HIV diagnoses.
$100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400 $100 $200 $300 $400.
EVALUATING STD PREVENTION: EXAMPLES FROM SYPHILIS AND VIRAL HEPATITIS National STD Conference March 11, 2004.
Let’s Play Who Wants to be a Millionaire! Lifelines Phone a friend, 50/50, Ask the audience.
CHAIN Workshop, 14 March 2014 Simon Collins: Health service constraints on HIV care – the research agenda: a UK perspective CHAIN Workshop,
World Hepatitis Day July 28th
Understanding the pathway: barriers to data collection and onward referral to specialist hepatitis C services for PWUD in London.
Dr John Dillon NHS Tayside Brian Stephens NHS Tayside Jan Tait NHS Tayside Daniel Kelly CAIR Scotland Ingrid Hainey CAIR Scotland Mike Burns CAIR Scotland.
Australia’s domestic HIV Strategy: 2014 and beyond Professor Chris Baggoley Chief Medical Officer Australian Government Department of.
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltd and sponsored by Bristol-Myers Squibb. None.
HIV and Hepatitis C in non- MSM Rural Communities: Issues and Interventions Shari Wells-Weiss, CASAC Director of Prevention Services Southern Tier AIDS.
Producing a Hepatitis C Improvement Framework through Partnership Working Dr. Éamonn O’Moore, FFPH. Director for Health & Justice, PHE. November 17 th,
Edo Agustian Indonesian Drug Users Network Experiencing HCV Infection – the treatment, the reality and the possibilities for Cure.
The perspective of a person with hepatitis C on new treatments and treatment as prevention Jack Wallace, Research Fellow. Australian Research Centre in.
Incorporating HIV and Viral Hepatitis Testing and Referral into Idaho Drug Court Programs Presented by Idaho Advisory Council on HIV and AIDS, Bebe Thompson,
Louisa Degenhardt 1, Bradley Mathers 1, Peter Vickerman 2, Tim Rhodes 3, Carl Latkin 4 and Matt Hickman 5 1.National Drug and Alcohol Research Centre,
Overview of the State of the HIV Epidemic in Canada Regional Session on USA and Canada XIX International AIDS Conference Howard Njoo MD, MHSc, FRCPC Director-General.
Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
All Change! Infections, injecting drug use and harm reduction. Vivian Hope IDU Team, HIV & STI Department, Health Protection Services – Colindale Dr Vivian.
Tackling hepatitis C - what PHE modelling shows us Helen Harris BSc PhD FFPH LJWG meeting; November 2014.
Injection drug use among men who have sex with men (MSM) Dr Adam Bourne Sigma Research London School of Hygiene & Tropical Medicine
Dr Ashley Brown Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, London and Honorary Senior Lecturer, Imperial College London The Updated.
Home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis Sabapathy K 1, Van den Bergh R 2, Fidler S 3, Hayes R 1,
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
Harm Reduction Team Maureen Woods Team Leader. Service Delivery Aims Develop harm reduction initiatives in partnership with other agencies to reduce the.
How aspirations can be built and levels of performance can be assured: Learning from the Scottish Action Plan Professor Sharon Hutchinson LJWG LDAPF Conference.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
QUALITY INDICATORS FOR HEPATITIS C Michele Hilton Boon Ray Fox, Clare Echlin, Scott Horton, Hepatitis C Project Group.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
#LJWG2015 HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
Social Work and Health Working in Partnership: Connecting the pieces Support & Care Treatment Prevention Recovery.
Hepatitis C policy development The Challenges The broad challenges General election No government liver strategy No clarity of who funds what No specific.
Family Medicine in the Health Care System. Module Objectives After this module the student will: 1. Understand the importance of family medicine in the.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
Hepatitis C and Sexual & Reproductive Health Graham Mackintosh, Training & Capacity Officer Lesley Bon, Patient Involvement Officer.
What is Hep C Dave Stafford.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Age-Standardised Five-Year Net Survival, England and Wales
Non-Hodgkin Lymphoma (C82-C85):
Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.
All Cancers Excluding Non-Melanoma Skin Cancer (C00-C97 Excl
Stomach Cancer (C16): Net Survival up to Ten Years after Diagnosis, Adults (Aged 15-99), England and Wales Please include the citation provided.
Age-Standardised One-Year Net Survival, England and Wales
Bladder Cancer (C67): One-, Five- and Ten-Year Net Survival (%), Adults Aged 15-99, England & Wales 1-Year 5-Year 10-Year Survival (%) Survival.
Ovarian Cancer (C56 C57.0-C57.7):
Cascade of care for persons newly diagnosed
Young People Newly Diagnosed with Hepatitis C in New York City
Global burden of HIV, viral hepatitis and TB in prisoners
HEPATITIS C IN PEOPLE WHO USE DRUGS Improving Care for Hepatitis C: A Framework Approach LONDON 2015.
Kidney Cancer (C64-C66 C68): One-, Five- and Ten-Year Net Survival (%), Adults Aged 15-99, England & Wales 1-Year 5-Year 10-Year Survival (%)
Lung Cancer (C33-C34): Age-Standardised Five-Year Net Survival, England and Wales Please include the citation provided in our Frequently Asked.
Edo Agustian Indonesian Drug Users Network
Brain Cancer (C71): One-, Five- and Ten-Year Net Survival (%), Adults Aged 15-99, England & Wales 1-Year 5-Year 10-Year Survival (%) Survival.
The cost-effectiveness of needle and syringe provision in preventing transmission of Hepatitis C Virus in people who inject drugs in the UK Zoë Ward1,
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
Brain Cancer (C71): Age-Standardised Five-Year Net Survival, England and Wales Please include the citation provided in our Frequently Asked Questions.
Brain Cancer (C71): Net Survival up to Ten Years after Diagnosis, Adults (Aged 15-99), England and Wales Please include the citation provided.
Hepatitis C case-finding – An opportunity for community pharmacy
Age-standardized* prevalence and number of cases of diagnosed diabetes among individuals aged 1 year and older, Canada, 1998/99 to 2008/09. *Age-standardized.
Presentation transcript:

Supporting people who use drugs & providers: hep C info & care Magdalena Harris London School of Hygiene and Tropical Medicine LJWG Conference - Hepatitis C in London – practical steps to elimination 17 November 2014, London.

Overview State of play in the UK: Prevention, testing & treatment? – What is the role of hep C literacy? Hepatitis C information needs: PWID & providers – Current resource provision Our response: LJWG & LSHTM partnership Information resource development & production The process …. The resources Next steps

The state of play in the UK …. Prevalence ~185,000 people living with chronic hep C Prevention 90% new cases due to use of unsterile injecting equipment Testing Only ~40% of people diagnosed: ~100,000 undiagnosed 36% of PWID attending drug services have never received a hep C test Treatment <3% receive treatment in the UK. Few are current PWID Elimination? Requires intensive scale up of prevention initiatives, case finding (often ex-PWID) & treatment provision for current PWID

What is the role of hep C literacy? For prevention – Enhance safe practices For testing – Reduce rates of undiagnosed For treatment – Increase access to & uptake of HCV treatment For health – Enable engagement in health care & HCV self management For empowerment – Enhance needed advocacy & activism

An information need: PWID Prevention Through them years, I have used a spoon that maybe someone else has used, but I’ve never used dirty works. You know, nothing dirty. (Max) Testing I’ve had boosters for hep C. I’m not due anymore boosters now. (Colin) Treatment With the treatment, you can’t use or drink alcohol or anything on top (Ivana) Hep C / cirrhosis I just want to know what’s going on with me, what do the pains mean? Can you tell, what is my [life] expectancy?... It’s scary because you haven’t got a clue what’s going on. (Frieda)

An information need: providers …. Missed opportunities for hep C prevention information Missed opportunities for testing Missed opportunities for treatment referral & initiation I was only diagnosed last June, but I had been backwards and forwards to the GP for many years just unwell and they did loads of tests, even gave me a hysterectomy, full hysterectomy, had the lot out... so I don’t know if that was necessary or not. (Jane) The [drug services] workforce haven’t got the right information so they don’t feel confident in helping someone to make the decision about treatment. (Focus group) I think that we lack the tools. Almost all that I do in consultation is verbal, and yet I’m a very visual person. I would much sooner somebody showed me in pictures what cirrhosis was … massively [ helpful] just to have a resource that I can show somebody what cirrhosis looks like. (Hepatologist)

Current resources Poor range & availability There’s nothing about hep C in the doctor’s surgery, there’s nothing about hep C in the hepatology clinic, you’d think that it’s about liver health, there’s nothing about hep C. (Sally) Language employed can be stigmatising, misleading, moralising “What kinds of people get hepatitis C...” “people around you are only at risk if they come in contact with your bodily fluids” “taking recreational drugs is dangerous and harmful to your health” Perceived as out of date / patronising … This is what is still on display in my GPs, this is ’03, they look dated … And the language in some of them, this is what I was given at [hospital] when we talked about treatment … the language used in that, I didn't like it at all, I found it very patronising. (Rita)

Our response …. Resource development plan (LJWG & LSHTM) Focus groups / workshops assessing need & developing content – Initial focus: treatment decision making resource Gilead support – making project tangible – Advisory board meeting, additional workshops, writer & designer A broader scope – Two booklets: Hep C info, Hep C care An iterative process – bottom up! – Resource development working group & advisory group

Wide range of involvement Role Workshop participation feedback Service users / PWID 510 BBV nurses 42 Drug service providers / leads 10 Researchers 20 Commissioners 21 Hepatitis C Trust staff 21 LJWG members 30 Public Health England 02 Industry 01 Total focus group/workshops & feedback: 20 month period Lambeth Service Users Council feedback

What was important? Clear, non-stigmatising language & visuals Rights rather than responsibility emphasis Harm reduction info acknowledging structural constraints to best practice Non-biased, not pushing treatment Drawing on research findings (re barriers & what is important to PWUD) Incorporating voices of people living with hepatitis C &/or PWUD Signposting links to other support

What was included? Resource 1: Hep C info Understanding hep C: prevalence, role of liver, natural history, cirrhosis, symptoms, transmission Testing: where to go, what it involves, antibody/PCR, testing reasons and rights, changing GP info, availability of DBS Disclosure: family/friends, work, finance, medical etc Staying safe: where to get injecting supplies, how to inject safely, tattooing / piercing info, transmission around the home /first aid Resource 2: Hep C Care Understanding hep C: genotypes, natural history, cirrhosis Living well with hep C – symptoms, self management, lifestyle Treatment: rights, eligibility (OST info, co-infection), testing / liver monitoring, new & current treatments, side effects, self management, support, appointment & medications, treatment pros & cons Support/ resource links (in both booklets)

Some examples Rights based All people with hep C are entitled to assessment and, unless there is a medical reason (contraindication) such as pregnancy, heart disease or severe depression, they are also entitled to treatment Real voices I come back and I told her, she was outside waiting for me, and she took one look at my face and she went, “It is isn’t it?” and I went, “Yeah,” and then I started crying and she went, “It’s alright, don’t worry about it, you know, I’ll do the test now and see if I’ve got it and if we have we’ll both start treatment and we do this together babe,”(Abel) Pragmatic harm reduction advice If you can’t clean a surface for preparing your hit or if you’re injecting outside, use a layer of tissue, toilet paper, or newspaper to lay your injecting equipment on.

Ongoing / next steps…. Workshop at 4 th National Recovery Conference, Glasgow Launch of resources at LJWG conference Resource circulation to Addaction South West, Blenheim CDP, Lambeth & Southwark Feedback collation, changes to content & redesign January 2015: larger print run & distribution Paper on process for peer-reviewed journal PHE has supported concept of wider roll out. Possible evaluation

Current design

Potential re-design

In summary Little knowledge among PWID about eligibility for treatment Little knowledge about new treatments on horizon Few referrals & treatment assessments despite eligibility Many missed opportunities for testing and diagnosis A desire for relevant hep C information: PWID & providers Resources were produced in partnership & through consultation Vital peers are central to any intervention development Information → advocacy → action I don’t think we can underestimate the impact of patient power or lobbying that actually brought about change in terms of accessing those drugs for people living with HIV. (Hepatologist)

Acknowledgements Everyone who took part in the resource development process!!! THANK YOU!!!! Lambeth Service Users Council Danny Morris, Jon Daniel, Dee Cunniffe, Nicola Brett, Claire Munro, David Badcock, Murad Ruf, Ashley Brown, David Nutt The Hepatitis C Treatment Journey study participants, partners & study sites. National Institute of Health Research, Gilead Sciences, LJWG Magdalena Harris is funded by a National Institute of Health Research Postdoctoral fellowship: NIHR-PDF